Neal Colleen H, Helvie Mark A
Department of Radiology, Breast Imaging Division, University of Michigan, Ann Arbor, MI, USA.
Department of Radiology, Breast Imaging Division, University of Michigan, Ann Arbor, MI, USA.
Radiol Clin North Am. 2021 Jan;59(1):19-27. doi: 10.1016/j.rcl.2020.09.005.
Since its widespread introduction 30 years ago, screening mammography has contributed to substantial reduction in breast cancer-associated mortality, ranging from 15% to 50% in observational trials. It is currently the best examination available for the early diagnosis of breast cancer, when survival and treatment options are most favorable. However, like all medical tests and procedures, screening mammography has associated risks, including overdiagnosis and overtreatment, false-positive examinations, false-positive biopsies, and radiation exposure. Women should be aware of the benefits and risks of screening mammography in order to make the most appropriate care decisions for themselves.
自30年前广泛引入以来，乳腺钼靶筛查已使乳腺癌相关死亡率大幅降低，在观察性试验中降低幅度为15%至50%。目前，在生存和治疗选择最为有利时，乳腺钼靶筛查是早期诊断乳腺癌的最佳检查方法。然而，与所有医学检查和程序一样，乳腺钼靶筛查也存在相关风险，包括过度诊断和过度治疗、假阳性检查、假阳性活检以及辐射暴露。女性应了解乳腺钼靶筛查的益处和风险，以便为自己做出最恰当的医疗决策。
